Phio Pharmaceuticals Corp. Email Format

Biotechnology ResearchPennsylvania, United States11-50 Employees

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on leveraging its INTASYL siRNA technology to enhance the ability of immune cells to kill tumor cells. The approach aims to precisely silence targeted genes in the body, potentially improving the effectiveness of immuno-oncology therapies. Based in King of Prussia, Pennsylvania, the company operates within the biotechnology research sector and targets cancer patients through its pipeline, including its lead candidate PH-762, evaluated as an intratumoral therapy for skin cancers and other malignancies.
Phio serves researchers and clinicians developing cancer treatments by providing a platform intended to empower immune responses against tumors. As a small-to-mid-sized organization in biopharma, it engages in early-stage clinical work and partnerships to advance its therapeutic approach, with recent activity including presentations at investor events and collaborations for manufacturing and distribution of PH-762.

Get verified Phio Pharmaceuticals Corp. emails free

Company overview Employee directory